Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the University of Oxford have discovered that male fruit flies adjust their seminal fluid depending on the levels of competition from other males.

When more rivals are around, they create and add extra protein to their seminal fluid making it extra potent. This boosts the number of offspring their partners produce, but the extra effort comes at a cost: it tires the male out and makes him sluggish to remate.

It previously wasn’t known if sperm and seminal fluid could be changed independent of each other, but this research shows that it can.

Humans also transfer both sperm and seminal fluid during ejaculation and this finding could suggest a new understanding of factors affecting fertility. It may also suggest novel treatment avenues for the current male ‘fertility crisis’, evidenced by human sperm counts declining steeply over the past 40 years.

The researchers’ data, published today in PNAS, suggest that male fruit flies use different rules for changing different parts of semen. If exposed to one or many rivals the researchers observed increases in sperm transfer compared to zero rivals. However, with seminal protein they observed increases in protein transfer in the presence of many compared to one or zero.

Read more (University of Oxford website)

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.